Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy.

Tambotatug pelitecan significantly improves survival and response rates in relapsed small-cell lung cancer compared to topotecan, with fewer severe adverse events.

• Why it matters: Effective treatments for relapsed small-cell lung cancer after platinum therapy are limited, and improving survival while reducing toxicity is crucial for patient outcomes.
• What they did: A phase 3 trial randomized 451 patients to receive tambotatug pelitecan or topotecan, assessing overall survival, progression-free survival, and objective response rates.
• The result: Patients treated with tambotatug pelitecan had a median overall survival of 13.3 months versus 9.4 months for topotecan, with higher response rates and fewer grade 3 or higher adverse events, enabling better treatment options.